Literature DB >> 33602344

Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems.

Julie Moltke1, Chandni Hindocha2,3,4.   

Abstract

BACKGROUND: Public and medical interest in cannabidiol (CBD) has been rising, and CBD is now available from various sources. Research into the effects of low-dose CBD on outcomes like stress, anxiety, and sleep problems have been scarce, so we conducted an online survey of CBD users to better understand patterns of use, dose, and self-perceived effects of CBD.
METHODS: The sample consisted of 387 current or past-CBD users who answered a 20-question online survey. The survey was sent out to CBD users through email databases and social media. Participants reported basic demographics, CBD use patterns, reasons for use, and effects on anxiety, sleep, and stress.
RESULTS: The sample (N = 387) consisted of 61.2% females, mostly between 25 and 54 years old (72.2%) and primarily based in the UK (77.4%). The top 4 reasons for using CBD were self-perceived anxiety (42.6%), sleep problems (42.5%), stress (37%), and general health and wellbeing (37%). Fifty-four per cent reported using less than 50 mg CBD daily, and 72.6% used CBD sublingually. Adjusted logistic models show females had lower odds than males of using CBD for general health and wellbeing [OR 0.45, 95% CI 0.30-0.72] and post-workout muscle-soreness [OR 0.46, 95%CI 0.24-0.91] but had higher odds of using CBD for self-perceived anxiety [OR 1.60, 95% CI 0.02-2.49] and insomnia [OR 1.87, 95% CI 1.13-3.11]. Older individuals had lower odds of using CBD for general health and wellbeing, stress, post-workout sore muscles, anxiety, skin conditions, focusing, and sleep but had higher odds of using CBD for pain. Respondents reported that CBD use was effective for stress, sleep problems, and anxiety in those who used the drug for those conditions.
CONCLUSION: This survey indicated that CBD users take the drug to manage self-perceived anxiety, stress, sleep, and other symptoms, often in low doses, and these patterns vary by demographic characteristics. Further research is required to understand how low doses, representative of the general user, might impact mental health symptoms like stress, anxiety, and sleep problems.

Entities:  

Keywords:  Anxiety; Cannabidiol; Internet-survey; Sleep; Stress; Sublingual

Year:  2021        PMID: 33602344      PMCID: PMC7893882          DOI: 10.1186/s42238-021-00061-5

Source DB:  PubMed          Journal:  J Cannabis Res        ISSN: 2522-5782


  67 in total

1.  Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

Authors:  David J Rog; Turo J Nurmikko; Tim Friede; Carolyn A Young
Journal:  Neurology       Date:  2005-09-27       Impact factor: 9.910

2.  Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report.

Authors:  Scott Shannon; Janet Opila-Lehman
Journal:  Perm J       Date:  2016-10-12

3.  The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells.

Authors:  Giuseppe Esposito; Daniele De Filippis; Rosa Carnuccio; Angelo A Izzo; Teresa Iuvone
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

4.  Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

Authors:  Mateus M Bergamaschi; Regina Helena Costa Queiroz; Marcos Hortes Nisihara Chagas; Danielle Chaves Gomes de Oliveira; Bruno Spinosa De Martinis; Flávio Kapczinski; João Quevedo; Rafael Roesler; Nadja Schröder; Antonio E Nardi; Rocio Martín-Santos; Jaime Eduardo Cecílio Hallak; Antonio Waldo Zuardi; José Alexandre S Crippa
Journal:  Neuropsychopharmacology       Date:  2011-02-09       Impact factor: 7.853

5.  A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.

Authors:  Derick T Wade; Philip Robson; Heather House; Petra Makela; Julia Aram
Journal:  Clin Rehabil       Date:  2003-02       Impact factor: 3.477

Review 6.  Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Authors:  A W Zuardi; J A S Crippa; J E C Hallak; F A Moreira; F S Guimarães
Journal:  Braz J Med Biol Res       Date:  2006-04-03       Impact factor: 2.590

7.  Age and racial differences in the presentation and treatment of Generalized Anxiety Disorder in primary care.

Authors:  Gretchen A Brenes; Mark Knudson; W Vaughn McCall; Jeff D Williamson; Michael E Miller; Melinda A Stanley
Journal:  J Anxiety Disord       Date:  2007-12-03

8.  Construct validation of self-reported stress scales.

Authors:  Erin Senesac Morgan; Katie Umberson; Christopher Hertzog
Journal:  Psychol Assess       Date:  2013-11-04

9.  Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series.

Authors:  Lucas Elms; Scott Shannon; Shannon Hughes; Nicole Lewis
Journal:  J Altern Complement Med       Date:  2018-12-13       Impact factor: 2.579

10.  Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users.

Authors:  Tory R Spindle; Edward J Cone; Elia Goffi; Elise M Weerts; John M Mitchell; Ruth E Winecker; George E Bigelow; Ronald R Flegel; Ryan Vandrey
Journal:  Drug Alcohol Depend       Date:  2020-04-01       Impact factor: 4.852

View more
  12 in total

1.  Development and initial psychometric properties of the Cannabidiol Outcome Expectancies Questionnaire (CBD-OEQ).

Authors:  Katherine Walukevich-Dienst; Paige E Morris; Raymond P Tucker; Amy L Copeland; Julia D Buckner
Journal:  Psychol Assess       Date:  2022-03-17

2.  The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials.

Authors:  Yuni Tang; Kolbi L Tonkovich; Toni Marie Rudisill
Journal:  Pharmaceut Med       Date:  2022-10-21

3.  Slovenian Pet Owners' Experience, Attitudes, and Predictors Regarding Cannabinoid Use in Dogs and Cats.

Authors:  Katerina Tomsič; Kristina Rakinić; Alenka Seliškar
Journal:  Front Vet Sci       Date:  2022-01-05

4.  Adherence, Safety, and Effectiveness of Medical Cannabis and Epidemiological Characteristics of the Patient Population: A Prospective Study.

Authors:  Lihi Bar-Lev Schleider; Raphael Mechoulam; Inbal Sikorin; Timna Naftali; Victor Novack
Journal:  Front Med (Lausanne)       Date:  2022-02-09

Review 5.  Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions.

Authors:  Jeremy D Henson; Luis Vitetta; Sean Hall
Journal:  Inflammopharmacology       Date:  2022-07-07       Impact factor: 5.093

6.  Cannabidiol use and perceptions in France: a national survey.

Authors:  Clémence Casanova; Clémence Ramier; Davide Fortin; Patrizia Carrieri; Julien Mancini; Tangui Barré
Journal:  BMC Public Health       Date:  2022-08-29       Impact factor: 4.135

7.  Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico.

Authors:  Flor Cristina Ortiz Rios; Itzel Guadalupe Dávila Ruiz; Elisa Sacal Dumani
Journal:  Drugs Context       Date:  2022-09-19

8.  Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.

Authors:  Kevin F Boehnke; Joel J Gagnier; Lynne Matallana; David A Williams
Journal:  J Pain       Date:  2021-06-30       Impact factor: 5.820

Review 9.  Enhancing Endocannabinoid Control of Stress with Cannabidiol.

Authors:  Jeremy D Henson; Luis Vitetta; Michelle Quezada; Sean Hall
Journal:  J Clin Med       Date:  2021-12-14       Impact factor: 4.241

Review 10.  Anti-Microbial Activity of Phytocannabinoids and Endocannabinoids in the Light of Their Physiological and Pathophysiological Roles.

Authors:  Ronit Vogt Sionov; Doron Steinberg
Journal:  Biomedicines       Date:  2022-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.